Transport Barriers in Transscleral Drug Delivery for Retinal Diseases
Transscleral delivery has emerged as an attractive method for treating retinal disorders because it offers localized delivery of drugs as a less invasive method compared to intravitreal administration. Numerous novel transscleral drug delivery systems ranging from microparticles to implants have bee...
Gespeichert in:
| Veröffentlicht in: | Ophthalmic research 2007-01, Vol.39 (5), p.244-254 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 254 |
|---|---|
| container_issue | 5 |
| container_start_page | 244 |
| container_title | Ophthalmic research |
| container_volume | 39 |
| creator | Kim, Stephanie H. Lutz, Robert J. Wang, Nam Sun Robinson, Michael R. |
| description | Transscleral delivery has emerged as an attractive method for treating retinal disorders because it offers localized delivery of drugs as a less invasive method compared to intravitreal administration. Numerous novel transscleral drug delivery systems ranging from microparticles to implants have been reported. However, transscleral delivery is currently not as clinically effective as intravitreal delivery in the treatment of retinal diseases. Transscleral drug delivery systems require drugs to permeate through several layers of ocular tissue (sclera, Bruch’s membrane-choroid, retinal pigment epithelium) to reach the neuroretina. As a result, a steep drug concentration gradient from the sclera to the retina is established, and very low concentrations of drug are detected in the retina. This steep gradient is created by the barriers to transport that hinder drug molecules from successfully reaching the retina. A review of the literature reveals 3 types of barriers hindering transscleral drug delivery: static, dynamic and metabolic. While static barriers have been examined in detail, the literature on dynamic and metabolic barriers is lacking. These barriers must be investigated further to gain a more complete understanding of the transport barriers involved in transscleral drug delivery. |
| doi_str_mv | 10.1159/000108117 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000108117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20927713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-7aa98ce281aa81b357a7833028cc3cff293e31772b8f79e265d0d92f28f9ee123</originalsourceid><addsrcrecordid>eNqF0UtLAzEQB_AgitbqwbvI4kHwsJrHZpMcta0PKAhSz0uaTsrWbbdOdoV-e9MHKl48hEDymz_MDCFnjN4wJs0tpZRRzZjaIx2WcZFSLs0-6VAqaCpUpo7IcQizqKQx9JAcMaUl43nWIYMR2kVY1tgk9xaxBAxJuUg2r8FVgLZK-thOkz5U5SfgKvE1Jq_QlIv1TxnABggn5MDbKsDp7u6St4fBqPeUDl8en3t3w9RlXDepstZoB1wzazUbC6ms0kJQrp0TzntuBAimFB9rrwzwXE7oxHDPtTcAjIsuudrmLrH-aCE0xbwMDqrKLqBuQ5FrYSSl8l_IqeFKMRHh5R84q1uMvUXDs1yaeCK63iKHdQgIvlhiObe4Khgt1hsovjcQ7cUusB3PYfIjdyOP4HwL3i1OAX9Fbeq_ABJih38</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224659465</pqid></control><display><type>article</type><title>Transport Barriers in Transscleral Drug Delivery for Retinal Diseases</title><source>Karger Journals</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kim, Stephanie H. ; Lutz, Robert J. ; Wang, Nam Sun ; Robinson, Michael R.</creator><creatorcontrib>Kim, Stephanie H. ; Lutz, Robert J. ; Wang, Nam Sun ; Robinson, Michael R.</creatorcontrib><description>Transscleral delivery has emerged as an attractive method for treating retinal disorders because it offers localized delivery of drugs as a less invasive method compared to intravitreal administration. Numerous novel transscleral drug delivery systems ranging from microparticles to implants have been reported. However, transscleral delivery is currently not as clinically effective as intravitreal delivery in the treatment of retinal diseases. Transscleral drug delivery systems require drugs to permeate through several layers of ocular tissue (sclera, Bruch’s membrane-choroid, retinal pigment epithelium) to reach the neuroretina. As a result, a steep drug concentration gradient from the sclera to the retina is established, and very low concentrations of drug are detected in the retina. This steep gradient is created by the barriers to transport that hinder drug molecules from successfully reaching the retina. A review of the literature reveals 3 types of barriers hindering transscleral drug delivery: static, dynamic and metabolic. While static barriers have been examined in detail, the literature on dynamic and metabolic barriers is lacking. These barriers must be investigated further to gain a more complete understanding of the transport barriers involved in transscleral drug delivery.</description><identifier>ISSN: 0030-3747</identifier><identifier>EISSN: 1423-0259</identifier><identifier>DOI: 10.1159/000108117</identifier><identifier>PMID: 17851264</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Biological Transport ; Humans ; Pharmaceutical Preparations - administration & dosage ; Pharmacokinetics ; Retinal Diseases - drug therapy ; Review ; Sclera - metabolism</subject><ispartof>Ophthalmic research, 2007-01, Vol.39 (5), p.244-254</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>(c) 2007 S. Karger AG, Basel.</rights><rights>Copyright (c) 2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-7aa98ce281aa81b357a7833028cc3cff293e31772b8f79e265d0d92f28f9ee123</citedby><cites>FETCH-LOGICAL-c428t-7aa98ce281aa81b357a7833028cc3cff293e31772b8f79e265d0d92f28f9ee123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17851264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Stephanie H.</creatorcontrib><creatorcontrib>Lutz, Robert J.</creatorcontrib><creatorcontrib>Wang, Nam Sun</creatorcontrib><creatorcontrib>Robinson, Michael R.</creatorcontrib><title>Transport Barriers in Transscleral Drug Delivery for Retinal Diseases</title><title>Ophthalmic research</title><addtitle>Ophthalmic Res</addtitle><description>Transscleral delivery has emerged as an attractive method for treating retinal disorders because it offers localized delivery of drugs as a less invasive method compared to intravitreal administration. Numerous novel transscleral drug delivery systems ranging from microparticles to implants have been reported. However, transscleral delivery is currently not as clinically effective as intravitreal delivery in the treatment of retinal diseases. Transscleral drug delivery systems require drugs to permeate through several layers of ocular tissue (sclera, Bruch’s membrane-choroid, retinal pigment epithelium) to reach the neuroretina. As a result, a steep drug concentration gradient from the sclera to the retina is established, and very low concentrations of drug are detected in the retina. This steep gradient is created by the barriers to transport that hinder drug molecules from successfully reaching the retina. A review of the literature reveals 3 types of barriers hindering transscleral drug delivery: static, dynamic and metabolic. While static barriers have been examined in detail, the literature on dynamic and metabolic barriers is lacking. These barriers must be investigated further to gain a more complete understanding of the transport barriers involved in transscleral drug delivery.</description><subject>Biological Transport</subject><subject>Humans</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pharmacokinetics</subject><subject>Retinal Diseases - drug therapy</subject><subject>Review</subject><subject>Sclera - metabolism</subject><issn>0030-3747</issn><issn>1423-0259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0UtLAzEQB_AgitbqwbvI4kHwsJrHZpMcta0PKAhSz0uaTsrWbbdOdoV-e9MHKl48hEDymz_MDCFnjN4wJs0tpZRRzZjaIx2WcZFSLs0-6VAqaCpUpo7IcQizqKQx9JAcMaUl43nWIYMR2kVY1tgk9xaxBAxJuUg2r8FVgLZK-thOkz5U5SfgKvE1Jq_QlIv1TxnABggn5MDbKsDp7u6St4fBqPeUDl8en3t3w9RlXDepstZoB1wzazUbC6ms0kJQrp0TzntuBAimFB9rrwzwXE7oxHDPtTcAjIsuudrmLrH-aCE0xbwMDqrKLqBuQ5FrYSSl8l_IqeFKMRHh5R84q1uMvUXDs1yaeCK63iKHdQgIvlhiObe4Khgt1hsovjcQ7cUusB3PYfIjdyOP4HwL3i1OAX9Fbeq_ABJih38</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Kim, Stephanie H.</creator><creator>Lutz, Robert J.</creator><creator>Wang, Nam Sun</creator><creator>Robinson, Michael R.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QO</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Transport Barriers in Transscleral Drug Delivery for Retinal Diseases</title><author>Kim, Stephanie H. ; Lutz, Robert J. ; Wang, Nam Sun ; Robinson, Michael R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-7aa98ce281aa81b357a7833028cc3cff293e31772b8f79e265d0d92f28f9ee123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological Transport</topic><topic>Humans</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pharmacokinetics</topic><topic>Retinal Diseases - drug therapy</topic><topic>Review</topic><topic>Sclera - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Stephanie H.</creatorcontrib><creatorcontrib>Lutz, Robert J.</creatorcontrib><creatorcontrib>Wang, Nam Sun</creatorcontrib><creatorcontrib>Robinson, Michael R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Biotechnology Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Stephanie H.</au><au>Lutz, Robert J.</au><au>Wang, Nam Sun</au><au>Robinson, Michael R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transport Barriers in Transscleral Drug Delivery for Retinal Diseases</atitle><jtitle>Ophthalmic research</jtitle><addtitle>Ophthalmic Res</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>39</volume><issue>5</issue><spage>244</spage><epage>254</epage><pages>244-254</pages><issn>0030-3747</issn><eissn>1423-0259</eissn><abstract>Transscleral delivery has emerged as an attractive method for treating retinal disorders because it offers localized delivery of drugs as a less invasive method compared to intravitreal administration. Numerous novel transscleral drug delivery systems ranging from microparticles to implants have been reported. However, transscleral delivery is currently not as clinically effective as intravitreal delivery in the treatment of retinal diseases. Transscleral drug delivery systems require drugs to permeate through several layers of ocular tissue (sclera, Bruch’s membrane-choroid, retinal pigment epithelium) to reach the neuroretina. As a result, a steep drug concentration gradient from the sclera to the retina is established, and very low concentrations of drug are detected in the retina. This steep gradient is created by the barriers to transport that hinder drug molecules from successfully reaching the retina. A review of the literature reveals 3 types of barriers hindering transscleral drug delivery: static, dynamic and metabolic. While static barriers have been examined in detail, the literature on dynamic and metabolic barriers is lacking. These barriers must be investigated further to gain a more complete understanding of the transport barriers involved in transscleral drug delivery.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>17851264</pmid><doi>10.1159/000108117</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-3747 |
| ispartof | Ophthalmic research, 2007-01, Vol.39 (5), p.244-254 |
| issn | 0030-3747 1423-0259 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000108117 |
| source | Karger Journals; MEDLINE; Alma/SFX Local Collection |
| subjects | Biological Transport Humans Pharmaceutical Preparations - administration & dosage Pharmacokinetics Retinal Diseases - drug therapy Review Sclera - metabolism |
| title | Transport Barriers in Transscleral Drug Delivery for Retinal Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A35%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transport%20Barriers%20in%20Transscleral%20Drug%20Delivery%20for%20Retinal%20Diseases&rft.jtitle=Ophthalmic%20research&rft.au=Kim,%20Stephanie%20H.&rft.date=2007-01-01&rft.volume=39&rft.issue=5&rft.spage=244&rft.epage=254&rft.pages=244-254&rft.issn=0030-3747&rft.eissn=1423-0259&rft_id=info:doi/10.1159/000108117&rft_dat=%3Cproquest_cross%3E20927713%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224659465&rft_id=info:pmid/17851264&rfr_iscdi=true |